* Cardiome's partner steadymed submits u.s. New drug application for trevyent® for the treatment of pulmonary arterial hypertension

* Cardiome pharma corp - cardiome expects to file trevyent for european medicines agency and health canada approval by end of 2017. Source text for Eikon: Further company coverage: